The Manila Times

[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong sales growth momentum of 7% (CER) in the first nine months of 2025; full-year earnings outlook raised

Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong sales growth momentum of 7% (CER) in the first nine months of 2025; full-year earnings outlook raised ...

Incyte Corporation (INCY) Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic Cancer Transcript

Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic ...
Money Talks News on MSN

IV Therapy Clinics Boom, Despite Experts Warning of "Expensive Urine"

Hospital-grade IV treatments are now available at strip mall clinics for anyone willing to pay. Medical professionals warn ...
BabyCenter on MSN

Everything Epidural: What you should know about the common pain relief method

Other epidural side effects The best time to get an epidural during labor If you want to put off the decision on whether to ...

Evaxion A/S (EVAX) Discusses 2-Year Phase II Data and AI Immunology Platform in High-Risk Melanoma Transcript

Discusses 2-Year Phase II Data and AI Immunology Platform in High-Risk Melanoma October 22, 2025 10:30 AM EDTCompany ...

KEYTRUDA® (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC)

KEYTRUDA is indicated for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then ...